OptimizeRx (NASDAQ:OPRX) Raised to "Strong-Buy" at B. Riley

B. Riley upgraded shares of OptimizeRx (NASDAQ:OPRX - Free Report) to a strong-buy rating in a research note released on Wednesday, Marketbeat Ratings reports.

A number of other equities research analysts have also issued reports on the company. Barclays reduced their price target on OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Thursday, November 14th. Lake Street Capital reissued a "buy" rating and set a $11.00 target price on shares of OptimizeRx in a research report on Tuesday, December 24th. Roth Mkm reissued a "buy" rating and set a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. JMP Securities reissued a "market outperform" rating and set a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. Finally, Stifel Nicolaus cut their target price on OptimizeRx from $13.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, OptimizeRx presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.06.

Remove Ads

OptimizeRx Stock Up 8.7 %

OPRX stock traded up $0.62 during mid-day trading on Wednesday, reaching $7.77. The company had a trading volume of 1,071,350 shares, compared to its average volume of 250,070. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The company has a market capitalization of $143.13 million, a price-to-earnings ratio of -5.84 and a beta of 1.31. The firm has a fifty day simple moving average of $5.53 and a 200 day simple moving average of $5.91. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $14.13.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of OPRX. Whetstone Capital Advisors LLC purchased a new stake in shares of OptimizeRx in the fourth quarter valued at about $6,563,000. Royce & Associates LP acquired a new position in OptimizeRx in the 4th quarter valued at about $5,198,000. Tang Capital Management LLC purchased a new stake in OptimizeRx during the 4th quarter valued at approximately $1,075,000. Kennedy Capital Management LLC lifted its position in OptimizeRx by 57.8% during the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock worth $2,887,000 after acquiring an additional 217,676 shares during the period. Finally, Walleye Capital LLC purchased a new position in shares of OptimizeRx in the 4th quarter valued at approximately $673,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.